According to a post on the FDA’s website, AstraZeneca’s treatment of Idiopathic Inflammatory Myopathies, anifrolumab, received orphan designation. Reference Link
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on AZN:
- AstraZeneca says Dato-DXd ‘continued to demonstrate encouraging responses’
- AstraZeneca’s Dato-DXd shows ‘durable efficacy’ in HER2-low patients
- Guardant Health announces collaboration with AstraZeneca
- AstraZeneca reports detailed results from SERENA-2 Phase 3 trial
- AstraZeneca reports results from SERENA-2 trial